Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company
AI-powered target discovery for a bacterial pathogen with a high medical need where no vaccine…
News
Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company
AI-powered target discovery for a bacterial pathogen with a high medical need where no vaccine…
Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference
CORAL GABLES, Fla., Sept. 18, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX),…
Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference
CORAL GABLES, Fla., Sept. 18, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX),…
Aruna Bio Announces Presentation on the Mechanism of its Neural Exosome Platform and Lead Program, AB126, at the BioProcess International Conference & Exhibition
– AB126, an unmodified exosome derived from neural stem cells, shows native therapeutic activity with anti-inflammatory…
Aruna Bio Announces Presentation on the Mechanism of its Neural Exosome Platform and Lead Program, AB126, at the BioProcess International Conference & Exhibition
– AB126, an unmodified exosome derived from neural stem cells, shows native therapeutic activity with anti-inflammatory…
Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)
– Topline results from this study are expected in early Q1 2024 – Celltrion has…
Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)
– Topline results from this study are expected in early Q1 2024 – Celltrion has…
Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer
Research will use Myriad’s high-definition MRD testing platform based on whole-genome sequencing SALT LAKE CITY,…
Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer
Research will use Myriad’s high-definition MRD testing platform based on whole-genome sequencing SALT LAKE CITY,…
TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned
Full ENVASARC accrual expected in Q4 and final data expected in mid-2024 SAN DIEGO, Sept….
TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned
Full ENVASARC accrual expected in Q4 and final data expected in mid-2024 SAN DIEGO, Sept….
Apnimed Appoints John Yee, MD, MPH, as SVP, Medical Affairs
– Seasoned biopharma medical leader joins Apnimed as it initiates its Phase 3 clinical program…
Apnimed Appoints John Yee, MD, MPH, as SVP, Medical Affairs
– Seasoned biopharma medical leader joins Apnimed as it initiates its Phase 3 clinical program…
Medigene AG Announces Lead Selection for MDG2011 Representing the First TCR-T Therapy of its KRAS Library
Planegg/Martinsried, September 18, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology…
Medigene AG Announces Lead Selection for MDG2011 Representing the First TCR-T Therapy of its KRAS Library
Planegg/Martinsried, September 18, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology…
Ambrx to Participate in the Cantor Fitzgerald Global Healthcare Conference
Morgan Stanley Fireside Chat Replay Now Available SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) —…
Ambrx to Participate in the Cantor Fitzgerald Global Healthcare Conference
Morgan Stanley Fireside Chat Replay Now Available SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) —…
POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands
Enables the efficient expansion of surface targets for radioisotope delivery INDIANAPOLIS and SCHLIEREN-ZURICH, Switzerland, Sept….
POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands
Enables the efficient expansion of surface targets for radioisotope delivery INDIANAPOLIS and SCHLIEREN-ZURICH, Switzerland, Sept….